Chiral aromatase and dual aromatase−steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activity

Paul M. Wood, L. W. Lawrence Woo, Jean-Robert Labrosse, Melanie N. Trusselle, Sergio Abbate, Giovanna Longhi, Ettore Castiglioni, France Lebon, Atul Purohit, Michael J. Reed, Barry V. L. Potter

Research output: Contribution to journalArticlepeer-review

68 Citations (Scopus)

Abstract

To explore aromatase inhibition and to broaden the structural diversity of dual aromatase-sulfatase inhibitors (DASIs), we introduced the steroid sulfatase (STS) inhibitory pharmacophore to letrozole. Letrozole derivatives were prepared bearing bis-sulfamates or mono-sulfamates with or without adjacent substituents. The most potent of the achiral and racemic aromatase inhibitor was 40 (IC50 = 3.0 nM). Its phenolic precursor 39 was separated by chiral HPLC and the absolute configuration of each enantiomer was determined using vibrational and electronic circular dichroism in tandem with calculations of the predicted spectra. Of the two enantiomers, (R)-phenol (39a) was the most potent aromatase inhibitor (IC50 = 0.6 nM, comparable to letrozole), whereas the (S)-sulfamate, (40b) inhibited STS most potently (IC50 = 553 nM). These results suggest that a new structural class of DASI for potential treatment of hormone-dependent breast cancer has been identified, and this is the first report of STS inhibition by an enantiopure nonsteroidal compound.
Original languageEnglish
Pages (from-to)4226-4238
JournalJournal of Medicinal Chemistry
Volume51
Issue number14
DOIs
Publication statusPublished - 2008

Fingerprint Dive into the research topics of 'Chiral aromatase and dual aromatase−steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and <em>in vitro</em> activity'. Together they form a unique fingerprint.

Cite this